top of page
Executive Spotlights

Summit bets $5B on Akeso, $500million upfront, and milestone payments of $4B for cancer therapy deal

Cambridge, MA, December 6, 2022 (Reuters) -- Summit Therapeutics Inc (SMMT.O) said on Tuesday it would license China-based Akeso Inc's (9926.HK) experimental cancer therapy in a deal worth up to $5 billion, sending its shares up 57% in premarket trade.


Read full article here.


Recent Posts

See All

Rahway, NJ & Cambridge, MA, November 21, 2023 (Business Wire) -- Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. declare a definitive agr

Life Science Headlines
bottom of page